Polish medtech company Quantum Innovations has raised €9.4 million in funding. The round was led by Vinci IQ ASI, a fund established by BGK and managed by Vinci S.A., with participation from the company’s existing investor, MedTech Holding.
Working along the same lines, ForSight Robotics, an Israeli eye surgery robotics startup, and Ganymed Robotics, which develops surgery robots raised funding.
How will it use the funding?
The capital raised in the current round of financing will be used to establish their production line, conduct regulatory and clinical trials, obtain certification, and enter major global markets.
It will be used to develop and set up a production line in a clean-room environment and conduct necessary certifications, including regulatory and clinical trials on humans, which will help bring the product to global markets.
“We were convinced to invest primarily by the groundbreaking product and technology, as well as the practical experience of the team. The solutions proposed by QI address an unmet need in clinical practice during cardiothoracic surgeries. Introducing these solutions into medical standards has the potential to significantly reduce complications and perioperative mortality associated with heart surgeries. Investments in medical technologies like QI fit perfectly with our fund’s mission of supporting sustainable development,” commented Piotr Woliński, President of Vinci S.A., which manages the Vinci IQ ASI fund.
What challenge does it tackle?
Cardiac surgery represents one of the most dynamically developing fields of medicine, having produced a significant number of breakthroughs and innovations over the past century. Despite these advances, cardiovascular diseases remain one of the two leading causes of mortality in developed countries. According to the latest World Heart Report 2023, over half a billion people worldwide suffer from cardiovascular diseases, which are responsible for nearly 20.5 million deaths, accounting for approximately 30% of all deaths.
The development of medical technologies significantly increases the success rate of cardiothoracic surgeries while reducing complications and mortality rates. Surgeries, especially those involving internal organs, require extreme precision and continuous monitoring. None of the currently available tools or equipment provide such capabilities. The technology developed by the Polish company Quantum Innovations aims to fill this gap.
What does Quantum Innovations do?
Founded by Grzegorz Suwalski and Przemysław Furdal, Quantum Innovations has developed the world’s first sensor technology for monitoring organs during surgery and for transplantation. The primary objective of the company’s devices is to increase the safety of invasive procedures performed in worldwide cardiac surgical centers.
Its Heart Sense solution enables real-time ECG monitoring directly from the surface of a beating heart. Additionally, Heart Guard technology tracks tissue metabolism, including during periods when the heart is stopped for cardiac surgery.
“Acquiring new and previously inaccessible precise signals from the organs and body parts undergoing surgery pushes the boundaries of our knowledge. Overcoming these barriers opens up prospects for improving medical procedures. Thus, Heart Sense technology makes it possible to examine the ECG of the operated heart, in any of its positions, from any of its walls, directly from its surface. Heart Guard technology, on the other hand, monitors the metabolism-dependent acidification of the heart. Studies indicate that using this data can help cardiac teams overcome knowledge gaps and prevent dangerous complications and fatalities in patients,” explained Grzegorz Suwalski, Founder and CEO of Quantum Innovations.
What do we think about Quantum Innovations?
The company is revolutionising cardiac surgery with its sensor technology for real-time organ monitoring, significantly enhancing surgical precision and patient safety. The funding will facilitate establishing production, certification, and global market entry. With its innovative technologies, Quantum Innovations is poised to reduce complications and mortality rates in cardiac surgeries, addressing critical unmet needs in clinical practice.
